Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19926551 | 0.98 | MAPT (0.57) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL17927787 | 0.94 | MAPT (0.49) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL549063 | 0.88 | DRD2 (0.59) | MAPTKDM4EGAAALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL17799458 | 0.86 | DRD2 (0.57) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL3112268 | 0.84 | PYGL (0.49) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL29622425 | 0.84 | PYGL (0.49) | MAPTKDM4EGAAALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL30142485 | 0.82 | PYGL (0.48) | MAPTKDM4EGAAALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL2144161 | 0.82 | PYGL (0.48) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL12079391 | 0.79 | HTR5A (0.37) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL5467312 | 0.78 | PYGL (0.45) | MAPTKDM4EGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119931978-A | Application of monoamine oxidase as catalyst in preparation of quinoline nitrogen heterocyclic compound | 河北工业大学 | 2025-05-06 | — | — | CN | claimed |
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | claimed |
| CN-117229275-B | Novel 2-acetamido thiazole compound and preparation method and application thereof | 北京中医药大学 | 2024-06-18 | — | — | CN | claimed |
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | claimed |
| CN-116376858-A | Application of monoamine oxidase from microorganism as catalyst in preparation of quinoline or quinoline derivative | 浙江大学杭州国际科创中心 | 2023-07-04 | — | — | CN | claimed |
| JP-1128982-A | — | — | None | — | — | JP | disclosed |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12624024-B2 | EP2 antagonist compounds | RESERVOIR NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4695253-A1 | IMIDAZO BICYCLIC DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695244-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695251-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695252-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2000064899-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-11-02 | — | — | WO | disclosed |
| CN-1261883-A | Novel compounds | SMITHKLINE BEECHAM PLC (GB) | 2000-08-02 | — | — | CN | disclosed |
| US-4912258-A | A 4-fluoroaniline compound | BOEHRINGER MANNHEIM GMBH (DE) | 1990-03-27 | — | — | US | disclosed |
| EP-0161482-B1 | FLUORINATED ANILINE DERIVATIVES AND THEIR USE | Roche Diagnostics GmbH (DE) | 1989-09-13 | — | — | EP | disclosed |
| JP-H01128982-A | METHOD FOR SYNTHESIZING BENZO (IJ) QUINOLIZINE-2-CARBOXYLIC ACID DERIVATIVE | SPA SOC PRODOTTI ANTIBIOTICI SPA | 1989-05-22 | — | — | JP | disclosed |
| EP-0173208-A1 | Tetrahydroquinolin-1-yl-carbonyl-imidazole derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0161482-A1 | Fluorinated aniline derivatives and their use | Roche Diagnostics GmbH (DE) | 1985-11-21 | — | — | EP | disclosed |
| US-4015005-A | TRANQUILIZERS, SLEEP INDUCERS, CNS DEPRESSANTS | SANDOZ, INC. (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GPR119 | MAPT 4844/4885KDM4E 2314/4885GAA 3059/4885 |
| US-12624024-B2 | EP2 antagonist compounds | PTGER1, PTGER2, PTGER4 | MAPT 4846/4885KDM4E 1758/4885GAA 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.